Health Canada Publishes Phase Two Amendments to Medical Device Establishment Licence Modernization

Summary

Health Canada announced on June 17, 2026, that the Phase Two amendments to the Medical Device Establishment Licence (MDEL) modernization were formally published. The amendments will take effect on December 14, 2026. They remove the requirement for foreign distributors to hold an MDEL when selling products through a licensed Canadian importer, require MDEL holders to establish and maintain written procedures, and require MDEL applicants and holders to submit a supplier list. The changes reduce industry burden and improve transparency, with important compliance implications for Chinese medical device companies planning to export to Canada.

Source: Health Canada Medical Devices Announcements. Source URL: https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/medical-devices-compliance-bulletin/phase-two-our-work-modernize-licensing.html. Specific requirements are subject to the latest official publication by the regulatory authority.

Full Translation of the Health Canada Announcement

MDCP Bulletin, June 17, 2026, from the Medical Devices Compliance Program

On This Page

• Background
• About the Amended Regulations
• What This Means for MDEL Holders
• Contact Us

Background

Health Canada is modernizing the regulation of companies that hold a Medical Device Establishment Licence (MDEL). We committed in 2018-19 to modernize the MDEL framework, but the COVID-19 pandemic delayed this work.

Phase One amendments were published in the Canada Gazette, Part II, on June 17, 2024, and came into force on December 14, 2024. These amendments, intended to modernize compliance and enforcement oversight, were outlined in the Forward Regulatory Plan and the Regulatory Stock Review Plan.

We are now in Phase Two of the modernization work, focusing on reducing burden, promoting innovation and enhancing competitiveness.

On November 8, 2025, we invited stakeholders to review proposed amendments to the Medical Devices Regulations. The proposed amendments were pre-published in the Canada Gazette, Part I, followed by a 75-day comment period. We considered stakeholder feedback in developing the final amendments.

Learn more:

• Canada Gazette, Part I
• Canada Gazette, Part II
• Health Canada's 2025-2028 Regulatory Stock Review Plan
• Health Canada's 2026-2028 Forward Regulatory Plan
• Health and Bioscience Sector Regulatory Review Roadmap

About the Amended Regulations

The amendments will take effect on December 14, 2026, which is 180 days after publication in the Canada Gazette, Part II, on June 17, 2026.

Key amendments include:

• Removing the requirement for foreign distributors to hold an MDEL when they sell medical devices through a Canadian importer that holds an MDEL;
• Clarifying the requirement for MDEL holders to establish, implement and maintain written procedures;
• Requiring MDEL applicants and holders to provide a list of suppliers of the medical devices they import or distribute in Canada.

Learn more:

• Canada Gazette, Part II

What This Means for MDEL Holders

The amended regulations reduce industry burden and clarify regulatory requirements without compromising the health and safety of Canadians.

They also align with international regulations and improve transparency for medical devices imported into Canada.

We have updated the following documents to reflect the latest changes:

• Medical Device Establishment Licence Guidance (GUI-0016)
• Medical Device Establishment Licence Application Instructions (FRM-0292)
• How Health Canada Inspects Medical Device Establishments (GUI-0064)
• Guidance on Risk Classification for Medical Device Establishment Inspections (GUI-0079)

Note: We will replace the existing guidance with these updated versions after the amendments take effect in December 2026.

Over the next six months, we will work closely with regulated parties to raise awareness and promote compliance. We will also publish notices on compliance promotion activities and guidance document updates.

Contact Us

If you have questions, please email mdel.questions.leim@hc-sc.gc.ca.

Page details: 2026-06-17.

AIMEILI Regulatory Interpretation and Business Impact

AIMEILI view: Health Canada formally published the Phase Two amendments to the MDEL modernization on June 17, 2026, with an effective date of December 14, 2026. The amendments are significant for Chinese companies planning to export medical devices to Canada, particularly in relation to registration pathways, compliance documentation, supplier management and quality systems.

Removal of the Foreign Distributor MDEL Requirement

The amendments remove the requirement for foreign distributors to hold an MDEL when selling products through a Canadian importer that already holds an MDEL. This change simplifies market access for non-Canadian companies. If a Chinese manufacturer sells through a Canadian importer that is an MDEL holder, it no longer needs to apply separately for an MDEL, reducing administrative costs and compliance burden. However, the Chinese manufacturer must still ensure that its Canadian importer holds a valid MDEL and should establish a clear contractual relationship to define responsibilities.

Written Procedures for MDEL Holders

The amendments clarify that MDEL holders must establish, implement and maintain written procedures. Chinese companies should verify that their Canadian importers have complete quality management system documentation, including purchasing, storage, distribution and record management. If a Chinese manufacturer holds an MDEL as an importer, for example through a Canadian subsidiary, it must establish written procedures that meet Canadian requirements. This may involve alignment with standards such as ISO 13485 or MDSAP.

Supplier List and Supply Chain Transparency

The new rules require MDEL applicants and holders to provide a list of suppliers of the medical devices they import or distribute in Canada. This requirement improves supply chain transparency and requires companies to maintain complete traceability information from manufacturer to end user. Chinese manufacturers should ensure that product information, manufacturing address and device identifiers are accurately provided to their Canadian importers and should cooperate in updating the supplier list. Companies with multiple distributors should coordinate information centrally to avoid omissions or errors that could create compliance risk.

Technical Files, MDL Maintenance and Timing

The amendments do not directly change product registration requirements or clinical evaluation requirements. However, MDEL compliance indirectly affects maintenance of a Medical Device Licence (MDL). If a Chinese company's product is already registered in Canada through an MDL, the MDEL status of its Canadian importer or distributor may affect market distribution. Companies should complete a compliance review with Canadian partners before the effective date of December 14, 2026, update cooperation agreements, and ensure that quality system documentation meets the new requirements.

Business Impact: Opportunities and Challenges

The amendments reflect Health Canada's intent to simplify regulation and align with international practice. For Chinese companies, they present both opportunities and challenges. The opportunity is that removing the MDEL requirement for foreign distributors lowers the entry threshold for certain market access models. The challenge is that stricter supplier list and written procedure requirements require companies to strengthen supply chain management and document preparation. AIMEILI recommends that companies closely monitor Health Canada's updated guidance documents, including GUI-0016, and use the six-month awareness period to adjust compliance strategies for a smooth transition.

Frequently Asked Questions

Can the June 17, 2026 announcement be used directly as a submission basis?

Answer: No. This article is intended for preliminary understanding and project assessment. Formal submissions must still be based on the latest requirements of the target regulatory authority, the product classification conclusion and the company's actual documentation status.

What should companies do first after seeing this update?

Answer: Companies should first conduct a documentation gap assessment to determine whether the update affects the registration pathway, technical file, labelling, quality management system or post-market maintenance obligations.

Content Review and Scope

Author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI International Medical Device Registration Project Team.

Source principle: Official regulatory authorities, international organizations, standards bodies and public regulatory materials are prioritized; industry media and project experience are used only as supporting judgment.

Scope: This article is for preliminary understanding, document preparation and project planning. It does not replace the official requirements of the target regulatory authority, testing conclusions or legal advice.